B+
Bull case
25%
Probability
Target price
$40.00
+33.2% vs current
RIGL
RigelDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$28.00
-6.7% vs current
B-
Bear case
25%
Probability
Target price
$18.00
-40.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+43.6
Score
AI commentary
Primary-source earnings evidence is mixed but stable: Q1 delivered continued product-sales growth, profitability, guidance reaffirmation, and a manageable cash position, but higher spending and the Lilly termination keep the story from cleanly upgrading. Secondary post-print coverage in the packet was sparse and mostly recap-oriented, with no robust T+3 analyst revision set available; the May 7, 2026 anchor close of $26.24 suggests no obvious sustained rerating from the earnings follow-up. Given low coverage and limited delayed reaction evidence, this remains a cautious monitoring view rather than a high-conviction bullish call.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-15eventJune 15, 2026 Lilly collaboration termination and rights reversionMedium impact
Rigel said Eli Lilly will terminate the ocadusertib collaboration effective June 15, 2026, which removes future partnered milestone or royalty optionality even as Rigel regains rights to the program; this is a portfolio-reset event with mixed read-through rather than a clean positive [#8-K-2026-05-05].
2026-12-31catalystPost-earnings commercial execution and 2026 guidance holdHigh impact
Rigel reported Q1 2026 total revenue of $58.8 million, net product sales of $54.9 million, net income of $8.7 million, and reaffirmed 2026 total revenue guidance of $275 million to $290 million with expected full-year positive net income; the near-term question is whether TAVALISSE, GAVRETO, and REZLIDHIA can keep supporting that guide after a quarter with higher operating costs [#8-K-2026-05-05].
2026-12-31catalystR289 dose-expansion completion, RP2D selection, and initial dataHigh impact
Management said R289 enrollment in the Phase 1b lower-risk MDS dose-expansion study is ongoing, with recommended Phase 2 dose selection expected in 2H 2026 and preliminary dose-expansion data expected by year-end 2026; this remains the main pipeline re-rating lever but also the main source of execution uncertainty [#8-K-2026-05-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology